Psoriasis: Emerging therapeutic strategies

Nature Reviews Drug Discovery

Volumn 4, Issue 1, 2005, Pages 19-34

  Gottlieb, Alice B ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA INTERFERON; ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; BETA INTERFERON; CORTICOSTEROID; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EFALIZUMAB; ETANERCEPT; ETRETIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 1; INFLIXIMAB; INTERLEUKIN 12P40; INTERLEUKIN 2; LITHIUM; METHOTREXATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; PSORALEN; RETINOID; TRANSCRIPTION FACTOR RUNX1; TUMOR NECROSIS FACTOR; UNINDEXED DRUG;

CAUCASIAN; CHROMOSOME 14Q; CHROMOSOME 15Q; CHROMOSOME 16Q; CHROMOSOME 17Q; CHROMOSOME 19P; CHROMOSOME 1P; CHROMOSOME 1Q; CHROMOSOME 20P; CHROMOSOME 3Q; CHROMOSOME 4Q; CHROMOSOME 6P; CHROMOSOME 8Q; CLINICAL TRIAL; CONTACT DERMATITIS; DISEASE ACTIVITY; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; EXPERIENCE; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; INJECTION SITE REACTION; META ANALYSIS; PATHOGENESIS; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUVA; QUALITY OF LIFE; REVIEW; SKIN INFLAMMATION; STREPTOCOCCUS; SYSTEMATIC REVIEW; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; UNITED STATES;

ANIMALS; CLINICAL TRIALS; DRUG THERAPY; HUMANS; PSORIASIS;

EID: 12144281223     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1607     Document Type: Review

References (196)

1. Gottlieb, A. B. Novel immunotherapies for psoriasis: clinical research delivers new hope for patients and scientific advances. J. Invest. Dermatol. Symp. Proc. 9, 79-83 (2004).
2. Gottlieb, A. B. Psoriasis. Dis. Manag. Clin. Outcomes 1, 195-202 (1998).
3. Heydendael, V. M. R. et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N. Engl. J. Med. 349, 658-65 (2003).
4. Rapp, S. R., Feldman, S. R., Exum, M. L., Fleischer, A B. & Reboussin, D. M. Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol. 41, 401-407 (1999 ).
5. Krueger, G. et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation Patient-Membership Survey. Arch. Dermatol. 137, 280-284 (1998).
6. de Korte, J., Sprangers, M. A. G., Members, F. M. C. & Bos, J. D. Quality of life in patients with psoriasis: a systemic literature review. J. Invest. Dermatol. Symp. Proc. 9, 140-147 (2004).
7. Brockbank, J. & Gladman, D. Diagnosis and management of psoriatic arthritis. Drugs 62, 2447-2457 (2002).
8. Gottlieb, A. B. Psoriatic arthritis: a guide for dermatology nurses. Dermatol. Nursing 15, 107-118 (2003).
9. Farber, E. M., Nall, M. L. & Watson, W. Natural history of psoriasis in 61 twin pairs. Arch. Dermatol 109, 207-211 (1974).
10. Zhou, X. et al. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 6,100-element oligonucleotide array. Physiol. Genomics 13, 69-78 (2003).
11. Helms, C. et al. A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with increased susceptibility to psoriasis. Nature Genet. 35, 349-356 (2003).
12. Ellis, C. N. et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N. Engl. J. Med. 324, 277-284 (1991).
13. Bos, J. D. The pathomechanisms of psoriasis: the skin immune system and cyclosporin. Br. J. Dermatol. 118, 141-155 (1988).
14. Gottlieb, A. B. et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J. Invest. Dermatol. 98, 302-309 (1992).
15. Baker, B. S., Swain, A. F., Fry, L. & Valdimarsson, H. Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br. J. Dermatol. 11, 555-564 (1984).
16. Gottlieb, A. B. et al. Expression of HLA-DR molecules by keratinocytes and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. J. Exp. Med. 164, 1013-1028 (1986).
17. Gottlieb, A. B. & Krueger, J. G. in Psoriasis (ed. Dubertret, L.) 63-71 (ISED, Brescie, Italy 1994).
18. Gottlieb, A. B. Immunopathology and immunomodulation. Med. Dermatol. 19, 649-657 (2001).
19. Gottlieb, A. B. Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin. Immunol. 105, 105-116 (2002).
20. Wrone-Smith, T. & Nickoloff, B. J. Dermal injection of immunocytes induces psoriasis. J. Clin. Invest. 98, 1878-1887 (1996).
21. Gilhar, A., David, M., Ullmann, Y., Berkutski, T. & Kalish, R. S. T-lymphocyte dependence of psoriatic pathology in human psoriatic, skin grafted to SCID mice. J. Invest Dermatol. 109, 283-288 (1997).
22. Gottlieb, S. L. et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med. 1, 442-447 (1995).
23. Gottlieb, A. B., Bacha, P., Parker, K. & Strand, V. Use of the interleukin-2 fusion protein, DAB389IL-2, for the treatment of psoriasis. Dermatol. Ther. 5, 48-63 (1998).
24. Gottlieb, A. B. et al. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple dose, placebo-controlled study. J. Am. Acad. Dermatol 43, 595-604 (2000).
25. Gottlieb, A. B. et al. A multiple dose randomized doubleblind pacebo-controlled study to determine the efficacy and safety of a humanized anti-CD4 monoclonal antibody in the treatment of moderate to severe chronic psoriasis vulgaris. J. Invest. Dermatol. 110 678 (1998).
26. Khandke, L. et al. Cycloporine in psoriasis treatment: inhibition of keratinocyte cell-cycle progression in G1 independent of effects on transforming growth factor-α/epidermal growth factor receptor pathways. Arch. Dermatol. 127, 1172-1179 (1991).
27. Bachelez, H. et al. Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4. J. Autoimmun. 11, 53-62 (1998).
28. Austin, L. M., Coven, T. R., Bhardwaj, N., Steinman, R. & Krueger, J. G. Intraepidermal lymphocytes in psoriatic lesions are GMP-17 (TIA-1)+CD8+CD3+ CTLs as determined by phenotypic analysis. J. Cut. Pathol. 25, 79-88 (1998).
29. Weinshenker, B. G., Bass, B. H., Ebers, G. C. & Rice, G. P. A. Remission of psoriatic lesions with uromonab-CD3 (Orthoclone OKT3) treatment. J. Am. Acad Dermatol. 20, 1132-1133 (1989).
30. Krueger, J. The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol. 46 1-23 (2002).
31. Weinstein, G. D. Methotrexate: diagnosis and treatment drugs five years later. Ann. Intern. Med. 86, 199-204 (1977).
32. Bos, J. D., VanJoost, T., Powles, A. V., Meinardi, M. M. H. M. & Fry, L. Use of cyclospoirin in psoriasis. Lancet 23, 1500-1505 (1989).
33. Ellis, C. N. et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 256, 3110-3116 (1986).
34. Boyman, O. et al. Spontaneous development of psoriasis in a new animal model shows an essential rose for resident T cells and tumor necrosis factor α. J. Exp. Med. 199, 731-736 (2004).
35. Conrad, C. et al. Crucial role for intraepidermal T cells expressing the collagen-binding integrin α1β1 in psoriasis. J. Invest. Dermatol. 122, A14-079 (2004).
36. Springer, T. A. et al. The lymphocyte function-associated LFA-1, CD2, and LFA-2 molecules: cell adhesion receptors of the immune system. Ann. Rev. Immunol. 5, 223-252 (1987).
37. Springer, T. A. Adhesions receptors of the immune system. Nature 346, 425-434 (1990).
38. H cell-mediated immune responses of the skin. J. Invest. Dermatol. Symp. Proc. 9, 5-14 (2004).
39. Ridge, J. P., DiRosa, F. & Matzinger, P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer call. Nature 393, 474-478 (1998).
40. Schoenberger, S. P., Toes, R. E. M., VanDerVoort, E. I. H., Offringa, R. & Melief, C. J. M. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393, 480-483 (1998).
41. Bennett, S. R. M. et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393, 478-483 (1998).
42. June, C. H., Ledbetter, J. A., Linsley, P. S. & Thompson, C. B. Role of the CD28 receptor in T-cell activation. Immunol. Today 11, 211-216 (1990).
43. Abrams, J. R. et al. CTLA4Ig-mediated blockade of T-cell oostimulation in patients with psoriasis vulgaris. J. Clin. Invest. 103, 1243-1252 (1999).
44. Abrams, J. et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J. Exp. Med. 192, 681-94 (2000).
45. Krueger, J. G. et al. Blockade of T-cell costimulation with CTLA4Ig (BMS-188667) reverses pathologic inflammation and keratinocyte activation in psoriatic plaques. J. Invest. Dermatol. 108, 555 (1997).
46. Lebwohl, M. et al. CTLA4Ig (BMS-188667)-mediated blockade of T cell costimulation in patients with psoriasis vulgaris. J. Invest. Dermatol. 108, 570 (1997).
47. Gottlieb, A. B. et al. Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody. J. Am. Acad. Dermatol. 47, 692-700 (2002).
48. Gottlieb, A. B. et al. Evaluation and safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe psoriasis. Clin. Immunol. 111, 28-37 (2004).
49. Najarian, D. J. & Gottlieb, A. B. Connections between psoriasis and Crohns disease. J. Am. Acad. Dermatol. 48, 805-821 (2003).
50. Chaudhari, U. et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357, 1842-1847 (2001).
51. Gottlieb, A. B. et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor monoclonal antibody (Infliximab) treatment of moderate to severe psoriasis vulgaris. J. Am. Acad. Dermatol. 48, 68-75 (2002).
52. Gottlieb, A. B. et al. Infliximab monotherapy, provides rapid and sustained benefit for plaque-type psoriasis. J. Am. Acad. Dermatol. 48, 829-835 (2003).
53. Leonardi, C., Gottlieb, A. & Zitnik, R. Efficacy and safety of ENBREL (etanercept) in patients with psoriasis: results of a phase III study. J. Invest. Dermatol. 121, 409 (2003).
54. Gottlieb, A. B. et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch. Dermatol. 139, 1627-1632 (2003).
55. Gottlieb, A. B. et al. Infliximab induction therapy in patients with severe plaque-type psoriasis: A randomized, doubleblind, placbo-controlled trial. J. Am. Acad. Dermatol. (in the press)
56. Nickoloff, B. J., Mitra, R. S., Elder, J. T., Fisher, G. J. & Voorhees, J. J. Decreased growth inhibition by recombinant γ -interferon is associated with increased transforming growth factor-α production in keratinocytes cultured from psoriatic lesions. Br. J. Dermatol. 121, 161-174 (1989).
57. Grossman, R. M. et al. Interleukin-6 (IL-6) is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc. Natl Acad Sci. USA 86, 6367-6371 (1989).
58. Hancock, G. E., Kaplan, G. &Cohn, Z. A. Keratinocyte growth regulation by the products of immune cells. J. Exp. Med. 168, 1395-1402 (1988).
59. Braunstein, S. et al. GM-CSF activates regenerative epidermal growth and stimulates keratinocyte proliferation in human skin in vivo. J. Invest. Dermatol. 103, 601-604 (1994).
60. Rich, B. & Kupper, T. Cytokines: IL-20 - a new effector in skin inflammation. Curr. Biol. 11, R531-R534 (2001).
61. Romer, J. et al. Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol. J. Invest. Dermatol. 121, 1306-1311 (2003).
62. Heng, M., Kloss, S., Kuehn, C. & Chase, D. Significance and pathogenesis of basal keratinocyte herniations in psoriasis. J. Invest. Dermatol. 87, 362-366 (1986).
63. Vaccaro, M. et al. The dermoepidermal junction in psoriatic skin as revealed by scanning electron microscopy. Arch. Dermatol. Res. 291, 369-396 (1999).
64. Boehncke, W.-H., Wortmann, S., Kaufmann, R., Mielke, V. & Sterry, W. A subset of macrophages located along the basement membrane ('lining cells') is a characteristic histopathological feature of psoriasis. Am. J. Dermatopathol. 17, 139-144 (1995).
65. Mansbridge, J. N. & Knapp, A. M. Changes in keratinocyte maturation during wound healing. J. Invest Dermatol. 89, 253-263 (1987).
66. Smoller, B. A. et al. Recessive dystrophic epidermolysis bullosa skin displays a chronic growth-activated immunophenotype. Arch. Dermatol. 126, 78-83 (1990).
67. Krueger, J. G., Gilleaudeau, P., Kikuchi, T. & Lee, E. Psoriasis-related subpopulations of memory CD4+ and CD8+ T cells are selectively reduced by Alefacept. J. Invest Dermatol. 119, 345 (2002).
68. Wakita, H. & Takigawa, M. E-selectin and vascular cell adhesion molecule-1 are critical for initial trafficking of helper-inducer/memory T cells in psoriatic, plaques. Arch. Dermatol 130, 457-463 (1994).
69. daSilva, A. J. et al. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2+ cells. J. Immunol. 168, 4462-4471 (2002).
70. Ellis, C. N., Krueger, G. G. & Group, A. C. S. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N. Engl. J. Med. 345, 248-255 (2001).
71. Krueger, G. G. et al. Alefacept Clinical Study Group. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy an dtolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J. Am. Acad Dermatol. 47, 821-833 (2002).
72. Lebwohl, M. et al. An international, randomized, doubleblind, placebo-controlled phase 3 trial of intramuscular all in patients with chronic plaque psoriasis. Arch. Dermatol. 139, 719-727 (2003).
73. Gottlieb, A. B. et al. CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study J. Am. Acad. Dermatol. 49, 816-825 (2003).
74. Gottlieb, A. et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J. Am. Acad. Dermatol. 42, 428-435 (2000).
75. Kraan, M. C. et al. Alefacept treatment in psoriatic, arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum. 46, 2776-2784 (2002).
76. Gottlieb, A. B. et al. Psoriasis as a model for T-cell-mediated disease: Immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a monoclonal antibody. Arch. Derm. 138, 591-600 (2002).
77. Gottlieb, A. G. et al. Subcutaneously administered efalizumab (antiCD11a) improves signs and symptoms of moderate to severe plaque psoriasis. J. Cut. Med. Surg. 7, 198-207 (2003).
78. Lebwohl, M. et al. A Novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl J. Med. 349, 2004-2013 (2003)
79. Papp K., B. R. et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J. Am. Acad Dermatol. 45, 665-674 (2001).
80. Motensen, D. et al. The pharmacokinetics and pharmacodynamics of efalizumab following 12 weeks of subcutaneous treatment in subjects with moderate to severe plaque psoriasis in a phase I, open-label, multi-center study. J. Invest Dermatol. 121, 379 (2003).
81. Chamian, F. et al. Presence of 'inflammatory' dendritic cells in psoriasis vulgaris lesions and modulation by efalizumab (anti-CD11a). J. Invest, Dermatol. 122, A41-A245 (2004).
82. Gordon, K. B. et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 290, 3073-3080 (2004).
83. Gottlieb, A. B., Hamilton, T. K., Caro, I. & Gordon, K. B. Efficacy and safety outcomes of long-term efalizumab therapy in patients with moderate to severe plaque psoriasis: an update. J. Invest. Dermatol. 122, A57-A341 (2004).
84. Austin, L., Ozawa, M., Kikuchi, T. & Krueger, G. Intracellular TNF-α, IFN-γ, and IL-2 identify TC1 and TH1 effector populations in psoriasis vulgaris plaque lymphocytes: single-cell analysis by flow cytometry. J. Invest Dermatol. 110, 649 (1998).
85. Ettehadi, P., Greaves, M. W., Wallach, D., Aderka, D. & Camp, R. D. R. Elevated tumour necrosis factor-α (TNF-α) biological activity in psoriatic skin lesions. Clin. Exp. Immunol. 96, 146-151 (1994).
86. Ritchlin, C. T., Haas-Smith, S. A., Li, P., Hicks, D. G., Schwarz, E. M. Mechanisms of TNF-α- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J. Clin. Invest. 111, 821-831 (2003).
87. Gottlieb, A. B. et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J. Am. Acad. Dermatol. 48, 68-75 (2003).
88. Nickoloff, B. J. The immunologic and genetic basis of psoriasis. Arch. Dermatol. 135, 1104-1110 (1999).
89. Gottlieb, A. G. Clinical research helps elucidate the role of tumor necrosis factor-α in the pathogeesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes. Lupus 12, 192-196 (2003).
90. Weisfelner, M. E. & Gottlieb, A. B. The role of apoptosis in human epidermal keratinocytes. J. Drugs. Dermatol. 2, 385-391 (2003).
91. Mease, P. J. et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356, 385-390 (2000).
92. Konig, A. et al. Inflammatory infiltrate and interleukin-8 expression in the synovium of psoriatic arthritis - an immunohistochemical and mRNA analysis. Rheumatol. Int. 17, 159-168 (1997).
93. Veale, D., Barnes, L., Rogers, S. & Fitz, G. O. Immunohistochemical markers for arthritis in psoriasis. Ann. Rheum. Dis. 53, 450-454 (1994).
94. Hohler, T et al. A TNF-α promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J. Invest. Dermatol. 109, 562-565 (1997).
95. VanDenBrande, J. M. H. et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohns Disease. Gastroenterology 124, 1774-1785 (2003).
96. Scallon, B. et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther. 301, 418-426 (2002).
97. Scallon, B. J., Moore, M. A., Trinh, H., Knight, D. M. & Ghrayeb, J. Chimeric anti-TNF-α monoclonal anti-body cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 7, 251-259 (1995).
98. tenHove, T., vanMontfrans, C., Peppelenbosch, M. P. & vanDeventer, S. J. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50, 206-211 (2002).
99. Maini, R. et al. Infliximab (chimeric anti-tumour necrosis factor-α monoclonal antibody) versus placebo in theumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354, 1932-1939 (1999).
100. Targan, S. R. et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-α for Crohns disease. N. Engl. J. Med. 337, 1029-1035 (1997).
101. Present, D. H. et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340 1398-1401 (1999).
102. VanOosten, B. W. et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with monoclonal anti-tumor necrosis factor antibody CA2. Neurology 47 1531-1534 (1996).
103. Oh, C. J., Des, K. M. & Gottlieb, A. B. Treatment with anti-tumor necrosis factor-α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J. Am. Acad. Dermatol. 42, 829-830 (2000).
104. Gottlieb, A. B. et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, doubleblind, placebo-controlled trial. J. Am. Acad. Dermatol. 51, 534-542 (2004).
105. Antoni, C. et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum. 46, S381 (2002).
106. Antoni, C. et al. The one year results of the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 48, S285 (2003).
107. Mease, P. et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and the effect on disease progression. Arthritis Rheum. 50, 2264-2272 (2004).
108. Lovell, D. et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N. Engl J. Med. 342 763-769 (2000).
109. Moreland, I. W. et al. Longterm Safety and Efficacy of Etanercept in Patients with Rheumatoid Arthritis. J. Rheumatol. 28, 1238-1244 (2001).
110. Davis, J. C. et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis. Arthritis Rheum. 48, 3230-3236 (2003).
111. Leonardi, C. L. et al. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349, 2014-2022 (2003).
112. Gottlieb, A. B., Gordon, K. B., Wang, A. & Zitnik, R. Durability of treatment response following withdrawal from etanercept in psoriasis patients. J. Invest. Dermatol. 122, A51-306 (2004).
113. Gordon, K. B. et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J. Invest Dermatol. 122, A54-321 (2004).
114. Day, R. Adverse reactions to TNF-α inhibitors in rheumatoid arthritis. Lancet 359, 540-541 (2002).
115. Keystone, E. et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthritis Rheum. 50, 1400-1411 (2004).
116. Ellerin, T., Rubin, R. H. & Weinblatt, M. Infections and anti-tumor necrosis factor α therapy. Arthritis Rheum. 48, 3013-3022 (2003).
117. Lee, E. et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199, 125-130 (2004).
118. Kauffman, C. L. et al. Treatment of moderate-to-severe psoriasis with human monoclonal antibody to human IL-12. J. Invest Dermatol. 121, 353 (2003).
119. Kauffman, C. L. et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J. Invest Dermatol. 123, 1037-1044 (2004).
120. Heufler, C., Koch, F. & Schuler, G. Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J. Exp. Med. 167, 700-705 (1988).
121. Witmer-Pack, M. D., Olivier, W., Valinsky, J., Schuler, G. & Steinman, R. M. Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells. J. Exp. Med. 166, 1484-1498 (1987).
122. Kimber, I., Cumberbatch, M., Dearman, R. J., Bhushan, M. & Griffiths, C. E. M. Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization. Br. J. Dermatol. 142, 401-412 (2000).
123. McInnes, I. B., Gracie, J. A. & Liew, F. Y. Interleukin-18: a novel cytokine in inflammatory rheumatic disease. Arthritis. Rheum. 44, 1481-1483 (2001).
124. Ye, X. J., Tang, B., Kang, A. H., Myers, L. K. & Cremer, M. A. The roles of interleukin-18 in collagen-induced arthriis in the BB rat. Clin. Exp. Immunol. 136, 1365-2249 (2004).
125. Siegmund, B. et al. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-γ and TNF-α production. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281 R1264-R1273 (2001).
126. Jameson, S. C. Maintaining the norm: T-cell homeostasis. Nature Rev. Immunol. 2 547-555 (2002).
127. Ruckert, R. et al. Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis? J. Immunol. 165, 2240-2250 (2000).
128. Schon, M. P., Zollner, T. M. & Henning Boehncke, W. The molecular basis of lymphocyte recruitment to the skin: clues for pathogenesis and selective therapies of inflammatory disorders. J. Invest. Dermatol. 121, 951-962 (2003).
129. Fuhlbrigge, R. C., Kieffer, J. D., Armerding, D. & Kupper, T. S. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 389, 978-981 (1997).
130. Kupper, T. S. Immune and inflammatory processes in cutaneous tissues. Mechanisms and speculations. J. Clin. Invest. 86, 1783-1789 (1990).
131. Robert, C. & Kupper, T. S. Inflammatory skin diseases, T cells, and immune surveillance. Mech. Disease 341, 1817-1828 (1999).
132. Schon, M. P. et al. Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nature Med 8, 366-372 (2002).
133. Ikegami-Kuzuhara, A. Y., T., Ohmoto, H. Inoue, Y. Saito, T. Therapeutic potential of a novel synthetic selectin blocker, J-R9188 in allergic dermatitis. J. Pharmacol. 134, 1498-1504 (2001).
134. Shand, A. F. A. Potential therapeutic role for cytokine or adhesion molecule manipulation in Crohn's disease in the shadow of infliximab? Int. J. Colorectal. Dis. 18, 1-11 (2003).
135. Ghosh, S. et al. Natilizumab for active Crohn's disease. N. Engl. J. Med. 348, 24-32 (2003).
136. De Boer, O. et al. Increased expression of adhesion receptors in both lesional and non-lesional psoriatic skin. Arch. Dermatol. Res. 286, 304-311 (1994).
137. deBoer, O., Verhagen, C., Visser, A., Bos, J. & Das, P. Cellular interactions and adhesion molecules in psoriatic skin. Acta Derm. Venereol. Suppl. (Stockh.) 186, 15-18 (1994).
138. Griffiths, C. E. M., Voorhees, J. J. & Nickoloff, B. J. Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant γ interferon and tumor necrosis factor. J. Am. Acad. Dermatol. 20 617-629 (1989).
139. Lisby, S., Ralfkiaer, E., Rothlein, R. & Vejlsgaard, G. L. Intercellular adhesion molecule-I (ICAM-I) expression correlated to inflammation. Br. J. Dermatol. 120, 479-484 (1989).
140. Onuma, S. Immunohistochemical studies of infiltrating cells in early and chronic lesions of psoriasis. J. Dermatol. 21, 223-232 (1994).
141. Pauls, K. et al. Role of integrin αE(CD103)β7 for tissue-specific epidermal localization of CD8+ T lymphocytes. J. Invest. Dermatol. 117, 569-575 (2002).
142. Teraki, Y. & Shiohara, T. Preferential expression of αEβ7 integrin (CD103) on CD8+ T cells in the psoriatic epidermis: regulation by interleukins 4 and 12 and transforming growth factor-β. J. Invest Dermatol. 147, 1118-1126 (2002).
143. Nickoloff, B. J. Role of interferon-γ in cutaneous trafficking of lymphocytes with emphasis on molecular and cellular adhesion events. Arch. Dermatol. 124, 1835-1845 (1988).
144. Rich, B. IL-7 promotes Th1 cell differentiation. J. Invest Dermatol. 122, A124-753 (2004).
145. Ferenczi, K., Murphy, J., Krzysiek, R. & Kupper, T. S. CXCR6 and its logand are consecutively expressed in skin. J. Invest. Dermatol. 122, A130-777 (2004).
146. Xia, Y. P. et al. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 102, 161-168 (2003).
147. Detmar, M. Evidence for vascular endothelial growth factor (VEGF) as a modifier gene in psoriasis. J. Invest. Dermatol. 122 XIV-XV (2004).
148. Young, H. S., Summers, A. M., Bhushan, M., Brenchley, P. E. C. & Griffiths, C. E. Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J. Invest. Dermatol. 122, 209-215 (2004).
149. Austin, L., Ozawa, M., Kikuchi, T., Walters, I. & Krueger, J. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-γ, interleukin-2, and tumor necrosis factor-α, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic, patients. J. Invest. Dermatol. 113, 752-759 (1999).
150. Gottlieb, A. B., Luster, A D., Posnett, D. N. & Carter, D. M. Detection of a γ-interferon-induced protein (IP-10) in psoriatic plaques. J. Exp. Med. 168, 941-948 (1988).
151. Gottlieb, A. B. Immunologic mechanisms in psoriasis. J. Invest. Dermatol. 95, 18S-19S (1990).
152. Livden, J. K., Nilsen, R., Bjerke, J. R. & Matre, R. In situ localization of interferons in psoriatic lesions. Arch. Dermatol. Res. 281, 392-397 (1989).
153. Cooper, K. D. et al. Increased levels of an interleukin-1 inhibitor block interleukin-1 activity but not immunoreactivity of mRNA expression of interleukin-1β in psoriasis skin. J. Invest. Dermatol. 90, 552 (1988).
154. Matthews, S. J. & McCoy, C. Thalidomide: a review of approved and investigational uses. Clin. Ther. 25, 342-395 (2003).
155. Kumar, S., Broehm, J. & Lee, J. C. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nature Rev. Drug Discov. 2, 717-726 (2003).
156. Thomas, P. IL-4-induced immune deviation as therapy of psoriasis. Arch. Derm. Res. 293, 30 (2001).
157. Asadullah, K. et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J. Clin. Invest 101, 783-794 (1998).
158. Trepicchio, W. et al. IL-11 is an immune-modulatory cytokine which downregulates IL-12, Type 1 cytokines, and multiple inflammation-associated genes in patients with psoriasis. J. Invest. Dermatol. 112 598 (1999).
159. Krueger, J. G. et al. Successful in vivo blockade of CD25 (high-affinity iryterleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J. Am. Acad. Dermatol. 43, 448-458 (2000).
160. Altmeyer, P. et al. Antipsoriatic effect of fumaric acid derivatives. J. Am. Acad. Dermatol. 30, 977-981 (1994 ).
161. Hoefnagel, J., Thio, H., Willemze, R. & Bavinck, J. Longterm safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br. J. Dermatol. 149, 363-369 (2003).
162. Hoxtermann, S., Nuchel, C. & Altmeyer, P. Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis. Dermatology 196, 223-230 (1998).
163. Litjens, N. H. R. et al. Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines. Br. J. Dermatol. 148, 444-451 (2003).
164. Loewe, R. et al. Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E Expression in an NF-κ B-dependent manner. J. Invest. Dermatol. 117, 1363-1368 (2001).
165. Mrowietz, U., Christophers, E. & Altmeyer, P. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. Br. J. Dermatol. 138, 456-460 (1998).
166. Ockenfels, H., Schultewolter, T., Ockenfels, G., Funk, R. & Goos, M. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the asoriatic cytokine network. Br. J. Dermatol. 139, 390-395 (1998).
167. Thio, H., van der Schroeff, J., Nugteren-Huying, W. & Vermeer, B. Long-term systemic therapy with dimethylfumarate and monoethylfumarate (Fumaderm) in psoriasis. J. Eur. Acad. Dermatol. Venereol. 4, 35-40 (1995).
168. Zhu, K. & Mrowietz, U. Inhibition of dendritic cell differentiation by fumaric acid esters. J. Invest. Dermatol. 116 203-208 (2001).
169. Treumer, F., Zhu, K., Glaser, R. & Mrowietz, U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J. Invest. Dermatol. 121, 1383-1388 (2003).
170. Jones, E. L., Epinette, W. W., Hackney, V. C., Menendez, L. & Frost, P. Treatment of psoriasis with oral mycophenolic, acid. J. Invest. Dermatol. 65, 537-542 (1975).
171. Griffiths, D. L. & Gottlieb, A. Treatment with oral pimecrolimus significantly improves psoriasis with a clear dose-response effect. J. Invest Dermatol. 121, 391 (2003).
172. Singh, F. & Weinberg, J. M. Oral tazarotene and oral pimecrolimus: novel oral therapies in development for psoriasis. J. Drugs Dermatol. 3, 141-143 (2004).
173. Ihle, J. N. The Stat family in cytokine signaling. Curr. Opin. Cell. Biol. 13, 211-217 (2001).
174. Manning, A. M. & Davis, R. J. Targeting JNK for therapeutic benefit; from junk to gold? Nature Rev. Drug Discov. 2, 554-565 (2003).
175. Karin, M., Yamamoto, Y., & Wang, Q. M. The IKKNF-kappaB system: a treasure trove for drug development. Nature Rev. Drug Discov. 3, 17-26 (2004).
176. Lu, I. et al. Modulation of epidermal differentiation, tissue inflammation, and T-lymphocyte infiltration in posoriatic plaques by topical calcitriol. J. Cutan. Pathol. 23, 419-434 (1996 ).
177. Gottlieb, S. L. et al. Etretinate promotes keratinocyte terminal differentiation and reduces T-cell infiltration in psoriatic epidermis. J. Cutan. Pathol. 23, 404-418 (1996).
178. Gottlieb, A. B., Chaudhari, U., Baker, D. G., Perate, M. & Dooley, L. T. The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison. J. Drugs Dermatol. 3, 260-266 (2003).
179. Frederiksson, T. & Pettersson, U. Severe psoriasis oral therapy with a new retinoid. Dermatologica 157, 238-244 (1978).
180. Gladman, D. D. Effectiveness of psoriatic arthritis therapies. Sem. Arthritis Rheum. 33, 29-37 (2003).
181. Gladman, D. D. et al. Assessment of patients with psoriatic arthritis. A review of currently available measures. Arthritis Rheum. 50, 24-35 (2004).
182. Abbas, A. K. & Lichtman, A. H. Cellular and Molecular Immunology 506-521 (Elsevier, Philadelphia, 2003).
183. Vallat, V. P. et al. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J. Exp. Med. 180 283-296 (1994).
184. Ferenczi, K., Burack, L., Pope, M., Krueger, J. & Austin, L. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J. Autoimmun. 14, 63-78. (2000).
185. Duncan, J. I. et al. Soluble IL-2 receptor and CD25 cells in psoriasis: effects of cyclosporin A and PUVA therapy. Clin. Exp. Immunol. 85, 293-296 (1991).
186. Krueger, J. G. et al. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J. Exp. Med. 182, 2057-2068 (1995).
187. Hodak, E. et al. Climatotherapy at the Dead Sea is a remittive therapy for psoriasis: combined effects on epidermal and immunologic activation. J. Am. Acad. Dermatol. 49, 451-457 (2003).
188. Nickoloff, B. & Griffiths, C. γ-Interferon induces different keratinocyte expression of HLA-DR, DQ and intercellular adhesion molecule-1 (ICAM-1) antigens. J. Invest. Dermatol. 90, 592 (1988).
189. Kupper, T S. Immunologic targets in psoriasis. N. Engl J. Med. 349, 1987-1990 (2003).
190. Gottlieb, A. B. Clinical research helps elucidate the role of tumor necrosis factor-α (TNF-α) in the pathogenesis of T1 mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes. Lupus 12, 192-196 (2003).
191. Goebeler, M. et al. The C-X-C chemokine Mig is highly expressed in the papillae of psoriatic, lesions. J. Pathol. 184 89-95 (1998).
192. Homey, B. et al. Up-regulation of macrophage inflammatory protein-3 α/CCL20 and CC chemokine receptor 6 in psoriasis. J. Immunol. 164, 6621-32 (2000).
193. Das, P. et al. Differential expression of ICAM-1, E-selectin and VCAM-1 by endothelial cells in psoriasis and contact dermatitis. Acta Derm. Venereol. Suppl. (Stockh.) 186, 21-2 (1994).
194. Morganroth, G. S., Chan, L. S., Weinstein, G. D., Voorhees, J. J. & Cooper, K. D. Proliferating cells in psoriatic dermis are comprised primarily of T cells, endothelial cells, and factor XIIIa+ perivascular dendritic cells. J. Invest. Dermatol. 96, 333-340 (1991).
195. Nickoloff, B. J. & Griffiths, C. E. M. Lymphocyte trafficking in psoriasis: a new perspective emphasizing the dermal dendrocyte with active dermal recruitment mediated via endothelial cells followed by intra-epidermal T-cell activation. J. Invest. Dermatol. 95, 35S-37S (1990).
196. Gottlieb, A. B., Chang, C. K., Posnett, D. N., Fanelli, B. & Tam, J. P. Detection of transforming growth factor α in normal, malignant, and hyperproliferative human keratinocytes. J. Exp. Med. 167, 670-675 (1988).